Nicholas J Lodge1, Yu-Wen Li1, Frederick T Chin2, Douglas D Dischino3, Sami S Zoghbi4, Jeffrey A Deskus5, Ronald J Mattson5, Masao Imaizumi4, Rick Pieschl1, Thaddeus F Molski1, Masahiro Fujita4, Heidi Dulac6, Robert Zaczek1, Joanne J Bronson5, John E Macor5, Robert B Innis4, Victor W Pike4. 1. Department of Neuroscience Biology, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492-7660, USA. 2. Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, MD 20892, USA; Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA 94305-5484, USA. 3. Department of Radiochemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492-7660, USA. 4. Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, MD 20892, USA. 5. Department of Neuroscience Chemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492-7660, USA. 6. Department of Veterinary Sciences, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492-7660, USA.
Abstract
INTRODUCTION: A radioligand for measuring the density of corticotropin-releasing factor subtype-1 receptors (CRF1 receptors) in living animal and human brain with positron emission tomography (PET) would be a useful tool for neuropsychiatric investigations and the development of drugs intended to interact with this target. This study was aimed at discovery of such a radioligand from a group of CRF1 receptor ligands based on a core 3-(phenylamino)-pyrazin-2(1H)-one scaffold. METHODS: CRF1 receptor ligands were selected for development as possible PET radioligands based on their binding potency at CRF1 receptors (displacement of [(125)I]CRF from rat cortical membranes), measured lipophilicity, autoradiographic binding profile in rat and rhesus monkey brain sections, rat biodistribution, and suitability for radiolabeling with carbon-11 or fluorine-18. Two identified candidates (BMS-721313 and BMS-732098) were labeled with fluorine-18. A third candidate (BMS-709460) was labeled with carbon-11 and all three radioligands were evaluated in PET experiments in rhesus monkey. CRF1 receptor density (Bmax) was assessed in rhesus brain cortical and cerebellum membranes with the CRF1 receptor ligand, [(3)H]BMS-728300. RESULTS: The three ligands selected for development showed high binding affinity (IC50 values, 0.3-8nM) at CRF1 receptors and moderate lipophilicity (LogD, 2.8-4.4). [(3)H]BMS-728300 and the two (18)F-labeled ligands showed region-specific binding in rat and rhesus monkey brain autoradiography, namely higher binding density in the frontal and limbic cortex, and cerebellum than in thalamus and brainstem. CRF1 receptor Bmax in rhesus brain was found to be 50-120 fmol/mg protein across cortical regions and cerebellum. PET experiments in rhesus monkey showed that the radioligands [(18)F]BMS-721313, [(18)F]BMS-732098 and [(11)C]BMS-709460 gave acceptably high brain radioactivity uptake but no indication of the specific binding as seen in vitro. CONCLUSIONS: Candidate CRF1 receptor PET radioligands were identified but none proved to be effective for imaging monkey brain CRF1 receptors. Higher affinity radioligands are likely required for successful PET imaging of CRF1 receptors.
INTRODUCTION: A radioligand for measuring the density of corticotropin-releasing factor subtype-1 receptors (CRF1 receptors) in living animal and human brain with positron emission tomography (PET) would be a useful tool for neuropsychiatric investigations and the development of drugs intended to interact with this target. This study was aimed at discovery of such a radioligand from a group of CRF1 receptor ligands based on a core 3-(phenylamino)-pyrazin-2(1H)-one scaffold. METHODS:CRF1 receptor ligands were selected for development as possible PET radioligands based on their binding potency at CRF1 receptors (displacement of [(125)I]CRF from rat cortical membranes), measured lipophilicity, autoradiographic binding profile in rat and rhesus monkey brain sections, rat biodistribution, and suitability for radiolabeling with carbon-11 or fluorine-18. Two identified candidates (BMS-721313 and BMS-732098) were labeled with fluorine-18. A third candidate (BMS-709460) was labeled with carbon-11 and all three radioligands were evaluated in PET experiments in rhesus monkey. CRF1 receptor density (Bmax) was assessed in rhesus brain cortical and cerebellum membranes with the CRF1 receptor ligand, [(3)H]BMS-728300. RESULTS: The three ligands selected for development showed high binding affinity (IC50 values, 0.3-8nM) at CRF1 receptors and moderate lipophilicity (LogD, 2.8-4.4). [(3)H]BMS-728300 and the two (18)F-labeled ligands showed region-specific binding in rat and rhesus monkey brain autoradiography, namely higher binding density in the frontal and limbic cortex, and cerebellum than in thalamus and brainstem. CRF1 receptor Bmax in rhesus brain was found to be 50-120 fmol/mg protein across cortical regions and cerebellum. PET experiments in rhesus monkey showed that the radioligands [(18)F]BMS-721313, [(18)F]BMS-732098 and [(11)C]BMS-709460 gave acceptably high brain radioactivity uptake but no indication of the specific binding as seen in vitro. CONCLUSIONS: Candidate CRF1 receptor PET radioligands were identified but none proved to be effective for imaging monkey brain CRF1 receptors. Higher affinity radioligands are likely required for successful PET imaging of CRF1 receptors.
Authors: Elaine Jagoda; Carlo Contoreggi; Mei-Jing Lee; Chih-Hao K Kao; Lawrence P Szajek; Sam Listwak; Philip Gold; George Chrousos; Elisabeth Greiner; B Moon Kim; Arthur E Jacobson; Kenner C Rice; William Eckelman Journal: J Med Chem Date: 2003-08-14 Impact factor: 7.446
Authors: Ge Zhang; Ning Huang; Yu-Wen Li; Xiaoping Qi; Anne P Marshall; Xiao-Xin Yan; Geraldine Hill; Cynthia Rominger; Shimoga R Prakash; Rajagopal Bakthavatchalam; David H Rominger; Paul J Gilligan; Robert Zaczek Journal: J Pharmacol Exp Ther Date: 2003-04 Impact factor: 4.030
Authors: Beth A Fleck; Sam R J Hoare; Rebecca R Pick; Margaret J Bradbury; Dimitri E Grigoriadis Journal: J Pharmacol Exp Ther Date: 2012-02-22 Impact factor: 4.030
Authors: Jeffrey A Deskus; Douglas D Dischino; Ronald J Mattson; Jonathan L Ditta; Michael F Parker; Derek J Denhart; Dmitry Zuev; Hong Huang; Richard A Hartz; Vijay T Ahuja; Henry Wong; Gail K Mattson; Thaddeus F Molski; James E Grace; Larisa Zueva; Julia M Nielsen; Heidi Dulac; Yu-Wen Li; Mary Guaraldi; Michael Azure; David Onthank; Megan Hayes; Eric Wexler; Jennifer McDonald; Nicholas J Lodge; Joanne J Bronson; John E Macor Journal: Bioorg Med Chem Lett Date: 2012-09-07 Impact factor: 2.823
Authors: L W Hsin; E L Webster; G P Chrousos; P W Gold; W C Eckelman; C Contoreggi; K C Rice Journal: Bioorg Med Chem Lett Date: 2000-04-17 Impact factor: 2.823
Authors: Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman Journal: Bioorg Med Chem Date: 2015-06-19 Impact factor: 3.641
Authors: Jeffrey S Stehouwer; Chase H Bourke; Michael J Owens; Ronald J Voll; Clinton D Kilts; Mark M Goodman Journal: Bioorg Med Chem Lett Date: 2015-10-08 Impact factor: 2.823